Mometasone Furoate Nasal Spray plus Oxymetazoline Nasal Spray: Short-term Efficacy and Safety in Seasonal Allergic Rhinitis

Meltzer, Eli O.; Bernstein, David I.; Prenner, Bruce M.; Berger, William; Shekar, Tulin; Teper, Ariel

doi:10.2500/ajra.2013.27.3864

Cited by 41 publications

(55 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four RCTs were removed after the full text screening. At the end, 6 RCTs were included . The RCTs retrieval and selection process including reasons for exclusion are listed in Figure .…”

Section: Resultsmentioning

confidence: 99%

“…There were a total of 1071 participants with mean age of 36.7 years (reported in 5 trials) and 36.0% were male (reported in 5 trials). Three RCTs included patients with AR only while the other 3 RCTs included mixed population of AR and NAR.…”

Section: Resultsmentioning

confidence: 99%

“…All 6 RCTs used intranasal oxymetazoline for the decongestant, 2 RCTs used nasal drop, and the other 4 RCTs used nasal spray . None of the RCTs used oral decongestants.…”

Section: Resultsmentioning

confidence: 99%

“…Two RCTs used budesonide, 2 RCTs used mometasone furoate, and the other 2 RCTs used fluticasone furoate …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta‐analysis

Khattiyawittayakun

Seresirikachorn

Chitsuthipakorn

et al. 2018

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…Four RCTs were removed after the full text screening. At the end, 6 RCTs were included . The RCTs retrieval and selection process including reasons for exclusion are listed in Figure .…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta‐analysis

Khattiyawittayakun

Seresirikachorn

Chitsuthipakorn

et al. 2018

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…OXY has been demonstrated to have various antioxidant and anti-inflammatory properties in addition to its potent decongestive effect2425. Previous studies have demonstrated that the concomitant administration of MF and OXY may provide better improvements in AR patients, especially those with nasal congestion symptom262728293031. Therefore, the initial thought of this study was that this decongestant would improve airflow and nasal volume and that MF may act on the turbinate and AH tissue more fully and quickly.…”

Section: Discussionmentioning

confidence: 98%

Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial

Liu

Zhou

Zeng

et al. 2017

Sci Rep

View full text Add to dashboard Cite

In the clinic, approximately 30% of children with adenoid hypertrophy (AH) concomitant with allergic rhinitis (AR) report poor responses to intranasal steroids. To determine whether the combination of mometasone furoate (MF) and oxymetazoline (OXY) is more effective than either agent alone, we performed a two-stage, parallel, randomized, double-blind, double-dummy, clinical trial with 240 AH children with concomitant perennial AR. During the first stage, all children were randomly assigned to the MF or control group for six weeks of treatment. During the second stage, the non-responders from stage one were randomly assigned to 4 groups for 8 weeks of treatment that involved receiving the following treatments: MF/OXY, MF/placebo, placebo/OXY, or placebo/placebo. During the first stage of treatment, 39% of the responders treated with MF achieved greater reductions in total and individual symptom scores than did those on placebo. During the second stage of treatment, the nasal congestion scores of the MF/OXY group significantly decreased. The adenoid/choana ratio of the MF/OXY-treated group decreased and the nasal volume increased significantly. Our results suggest that the combination of OXY and MF is effective and safe for the treatment of AH children with concomitant AR and has a rapid onset of action.

show abstract

Combined medical therapy in the treatment of allergic rhinitis: Systematic review and meta‐analyses

Chitsuthipakorn

Hoang

Kanjanawasee

et al. 2022

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background: Antihistamines (ATH) and intranasal corticosteroids (INCS) are primary treatments for patients with allergic rhinitis (AR). When monotherapy of either primary treatment fails to control symptoms, combined medical therapy is an option. In this meta-analysis we assessed the additional effects of different medical combinations compared with primary treatments. Methods: Systematic searches on PubMed and EMBASE were updated on November 4, 2021. Randomized, controlled trials comparing the effects of combinations with monotherapy were included. There were 7 comparisons: (1) ATHdecongestant vs ATH; (2) ATH-leukotriene receptor antagonist (LTRA) vs ATH; (3) INCS-ATH vs INCS; (4) INCS-LTRA vs INCS; (5) INCS-decongestion vs INCS; (6) INCS-saline irrigation vs INCS; and (7) ATH-saline irrigation vs ATH. Data were pooled for meta-analysis. Outcomes were composite nasal symptom score, composite ocular symptom score, quality of life (QoL), and adverse events. Results: Fifty-three studies were included. Compared with ATH alone, the ATHdecongestant combination improved composite nasal symptoms; ATH-LTRA improved nasal symptoms in patients with perennial AR; and ATH-nasal saline improved both symptoms and QoL. Compared with INCS alone, the INCSintranasal ATH combination improved nasal symptoms, ocular symptoms, and QoL; INCS-LTRA improved ocular symptoms but not nasal symptoms; and INCS-nasal saline improved QoL but not symptoms. There were no additional effects observed from adding oral ATH or topical decongestant to INCS. Conclusion: After ATH monotherapy fails to control symptoms, addition of decongestant, saline, or LTRA can improve the outcomes. When INCS monotherapy is ineffective, addition of intranasal ATH can improve nasal symptoms; LTRA can improve ocular symptoms, and saline irrigation can improve QoL.

show abstract

Mometasone Furoate Nasal Spray plus Oxymetazoline Nasal Spray: Short-term Efficacy and Safety in Seasonal Allergic Rhinitis

Abstract: Combining MFNS with OXY relieves SAR symptoms, including congestion, with faster onset of action than MFNS q.d. and better sustained efficacy than OXY b.i.d.

Cited by 41 publications

References 20 publications

Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta‐analysis

Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta‐analysis

Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial

Combined medical therapy in the treatment of allergic rhinitis: Systematic review and meta‐analyses

Contact Info

Product

Resources

About